Nov. 2 at 2:18 AM
$TSHA "Heads up alert! Only three days until Upcoming earnings on Tuesday, 11/4/2025 for
$TSHA
Bullish (8.2)
Taysha Gene Therapies, Inc.
(TSHA) is positioned favorably within the biotechnology sector, particularly following its recent strategic advancements and regulatory milestones.
The company focuses on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases, with its lead candidate, TSHA-102, targeting Rett syndrome.
Taysha has regained full global rights to TSHA-102, a significant development that enhances its strategic flexibility and potential for long-term value creation.
Recent clinical trial results have shown a 100% response rate in the Phase 1/2 REVEAL trial, indicating promising safety and efficacy profiles.
Financially, TSHA's P/E ratio is currently not applicable due to its clinical-stage status, but the company is expected to improve its earnings per share (EPS) as it advances toward commercialization.
Analysts have set a consensus price target of
$9.42, reflecting optimism about the company's growth trajectory and potential market capitalization.
Comparatively, Taysha's performance metrics align favorably against industry peers, suggesting robust investor interest and confidence in its developmental pipeline.
Regarding upcoming earnings reports, Taysha is scheduled to release its third-quarter financial results on November 4, 2025.
Analysts are keenly observing this announcement, particularly in light of the company's recent achievements and the ongoing trial for TSHA-102.
Historical performance indicates volatility typical of clinical-stage biotechs, but the recent Breakthrough Therapy designation from the FDA is expected to bolster investor sentiment.
Analyst consensus estimates suggest that the market will be looking for indications of revenue growth and advancements in clinical trial timelines, which could significantly impact TSHA's stock price.
In the broader context, the healthcare sector has experienced a slight retreat recently, with the NYSE Health Care Index down by 0.4%.
This sector-wide trend could influence investor sentiment towards Taysha, but the company's unique advancements position it as a potential outlier.
The market's focus on innovative biotechnologies, particularly in gene therapy, remains strong, suggesting that Taysha could benefit from a favorable environment as it continues to progress in its clinical endeavors.
- Funds were net buyers of
$TSHA during the previous reporting quarter.
- Funds with large holdings in
$TSHA include:
- RTW Investments LP, MV:
$58MM. Fund Rank: 74%
www.rtwfunds.com
- RA Capital Management LLC, MV:
$54MM. Fund Rank: 60%
www.racap.com
- Avoro Capital Advisors LLC, MV:
$50MM. Fund Rank: 88%
avorocapital.com
- Point72 Asset Management LP, MV:
$17MM. Fund Rank: 91%
www.point72.com
- Deerfield Management Co, MV:
$12MM. New position. Fund Rank: 80%
www.deerfield.com
- Last 10 days performance: 0%
- Last 30 days performance: 2%
- Last 90 days performance: 89%
Some of the latest news articles:
- Title: Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Publication Date: 10/28/2025 12:00:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/taysha-gene-therapies-release-third-120000728.html?.tsrc=rss
- Title: Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102
Publication Date: 10/26/2025 10:43:12 AM, Source: yahoo
URL: https://finance.yahoo.com/news/taysha-gene-therapies-regains-full-104312052.html?.tsrc=rss
- Title: Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum
Publication Date: 10/26/2025 10:16:24 AM, Source: yahoo
URL: https://finance.yahoo.com/news/raymond-james-initiates-strong-buy-101624877.html?.tsrc=rss
- Title: How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story
Publication Date: 10/18/2025 12:18:12 AM, Source: yahoo
URL: https://finance.yahoo.com/news/regaining-full-rights-rett-syndrome-001812038.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
